199 related articles for article (PubMed ID: 24493028)
1. Therapeutic effectiveness of potassium iodine in drug-naïve patients with Graves' disease: a single-center experience.
Uchida T; Goto H; Kasai T; Komiya K; Takeno K; Abe H; Shigihara N; Sato J; Honda A; Mita T; Kanazawa A; Fujitani Y; Watada H
Endocrine; 2014 Nov; 47(2):506-11. PubMed ID: 24493028
[TBL] [Abstract][Full Text] [Related]
2. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Patients with Graves' Disease Whose Thyroid Hormone Levels Increase After Substituting Potassium Iodide for Methimazole in the First Trimester of Pregnancy.
Yoshihara A; Noh JY; Watanabe N; Kunii Y; Suzuki M; Matsumoto M; Suzuki N; Hiruma M; Morisaki M; Kawaguchi A; Sugino K; Ito K
Thyroid; 2020 Mar; 30(3):451-456. PubMed ID: 31928169
[No Abstract] [Full Text] [Related]
4. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
[TBL] [Abstract][Full Text] [Related]
5. Substituting Potassium Iodide for Methimazole as the Treatment for Graves' Disease During the First Trimester May Reduce the Incidence of Congenital Anomalies: A Retrospective Study at a Single Medical Institution in Japan.
Yoshihara A; Noh JY; Watanabe N; Mukasa K; Ohye H; Suzuki M; Matsumoto M; Kunii Y; Suzuki N; Kameda T; Iwaku K; Kobayashi S; Sugino K; Ito K
Thyroid; 2015 Oct; 25(10):1155-61. PubMed ID: 26222916
[TBL] [Abstract][Full Text] [Related]
6. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
7. RELATIONSHIP BETWEEN THE EFFECTIVENESS OF INORGANIC IODINE AND THE SEVERITY OF GRAVES THYROTOXICOSIS: A RETROSPECTIVE STUDY.
Honda A; Uchida T; Komiya K; Goto H; Takeno K; Sato J; Suzuki R; Himuro M; Watada H
Endocr Pract; 2017 Dec; 23(12):1408-1413. PubMed ID: 29144795
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine uptake after monotherapy with potassium iodide in patients with Graves' disease.
Mikura K; Yoshimura Noh J; Watanabe N; Aida A; Yoshimura R; Kinoshita A; Suzuki A; Suzuki N; Fukushita M; Matsumoto M; Yoshihara A; Sugino K; Ito K
Endocr J; 2023 May; 70(5):541-549. PubMed ID: 36843112
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.
Mazza E; Carlini M; Flecchia D; Blatto A; Zuccarini O; Gamba S; Beninati S; Messina M
J Endocrinol Invest; 2008 Oct; 31(10):866-72. PubMed ID: 19092290
[TBL] [Abstract][Full Text] [Related]
10. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease.
Xu B; Wu D; Ying H; Zhang Y
Turk J Med Sci; 2019 Jun; 49(3):715-722. PubMed ID: 31023005
[TBL] [Abstract][Full Text] [Related]
11. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A
Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623
[TBL] [Abstract][Full Text] [Related]
12. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
Huang CN; Hsu TC; Chou HH; Tsay GJ
J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
[TBL] [Abstract][Full Text] [Related]
14. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease.
Roti E; Robuschi G; Gardini E; Montermini M; Salvi M; Manfredi A; Gnudi A; Braverman LE
Clin Endocrinol (Oxf); 1988 Mar; 28(3):305-14. PubMed ID: 3168311
[TBL] [Abstract][Full Text] [Related]
15. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial.
Azizi F; Abdi H; Amouzegar A
BMC Endocr Disord; 2021 Jan; 21(1):16. PubMed ID: 33446181
[TBL] [Abstract][Full Text] [Related]
16. The change in 123I-uptake between 3- and 24-hours is useful in predicting early response to methimazole in patients with Graves' disease.
Gemma R; Nakamura H; Mori T; Andoh S; Suzuki Y; Yoshimi T
Endocr J; 1996 Feb; 43(1):61-6. PubMed ID: 8732453
[TBL] [Abstract][Full Text] [Related]
17. Iodide-sensitive Graves' hyperthyroidism and the strategy for resistant or escaped patients during potassium iodide treatment.
Okamura K; Sato K; Fujikawa M; Bandai S; Ikenoue H; Kitazono T
Endocr J; 2022 Aug; 69(8):983-997. PubMed ID: 35321988
[TBL] [Abstract][Full Text] [Related]
18. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
Kubota S
Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
[TBL] [Abstract][Full Text] [Related]
19. Very rare case of Graves' disease with resistance to methimazole: a case report and literature review.
Mori Y; Hiromura M; Terasaki M; Kushima H; Ohara M; Fukui T; Takahashi Y; Yamagishi SI
J Int Med Res; 2021 Mar; 49(3):300060521996192. PubMed ID: 33682498
[TBL] [Abstract][Full Text] [Related]
20. Fetal Goitrous Hyperthyroidism in a Pregnant Woman with Triiodothyronine-Predominant Graves' Disease.
Washio K; Uenaka M; Tanimura K; Deguchi M; Nishida K; Fujioka K; Yamada H
Kobe J Med Sci; 2021 Feb; 66(4):E153-E158. PubMed ID: 33994519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
